Literature DB >> 24900886

Discovery of a New Series of Naphthamides as Potent VEGFR-2 Kinase Inhibitors.

Yongcong Lv1, Mengyuan Li2, Ting Liu3, Linjiang Tong4, Ting Peng4, Lixin Wei5, Jian Ding4, Hua Xie4, Wenhu Duan1.   

Abstract

Inhibition of VEGFR-2 signaling pathway has already become one of the most promising approaches for the treatment of cancer. In this study, we describe the design, synthesis, and biological evaluation of a new series of naphthamides as potent inhibitors of VEGFR-2. Among these compounds, 14c exhibited high VEGFR-2 inhibitory potency in both enzymatic and HUVEC cellular proliferation assays, with IC50 values of 1.5 and 0.9 nM, respectively. Kinase selectivity profiling revealed that 14c was a multitargeted inhibitor, and it also exhibited good potency against VEGFR-1, PDGFR-β, and RET. Furthermore, 14c effectively blocked tube formation of HUVEC at nanomolar level. Overall, 14c might be a promising candidate for the treatment of cancer.

Entities:  

Keywords:  Angiogenesis; HUVEC; VEGFR-2; inhibitor; naphthamide

Year:  2014        PMID: 24900886      PMCID: PMC4027589          DOI: 10.1021/ml5000417

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  22 in total

Review 1.  VEGF receptor signalling - in control of vascular function.

Authors:  Anna-Karin Olsson; Anna Dimberg; Johan Kreuger; Lena Claesson-Welsh
Journal:  Nat Rev Mol Cell Biol       Date:  2006-05       Impact factor: 94.444

Review 2.  Clinical implications of circulating angiogenic factors in cancer patients.

Authors:  R T Poon; S T Fan; J Wong
Journal:  J Clin Oncol       Date:  2001-02-15       Impact factor: 44.544

3.  Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors.

Authors:  Francesca Musumeci; Marco Radi; Chiara Brullo; Silvia Schenone
Journal:  J Med Chem       Date:  2012-11-06       Impact factor: 7.446

Review 4.  Vascular-targeting therapies for treatment of malignant disease.

Authors:  Dietmar W Siemann; David J Chaplin; Michael R Horsman
Journal:  Cancer       Date:  2004-06-15       Impact factor: 6.860

Review 5.  Development and strategies of VEGFR-2/KDR inhibitors.

Authors:  Lingyi Huang; Zhengui Huang; Zhiqiang Bai; Rui Xie; Liping Sun; Kejiang Lin
Journal:  Future Med Chem       Date:  2012-09       Impact factor: 3.808

6.  Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.

Authors:  Y Takahashi; Y Kitadai; C D Bucana; K R Cleary; L M Ellis
Journal:  Cancer Res       Date:  1995-09-15       Impact factor: 12.701

7.  Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.

Authors:  Daniel S La; Julie Belzile; James V Bready; Angela Coxon; Thomas DeMelfi; Nicholas Doerr; Juan Estrada; Julie C Flynn; Shaun R Flynn; Russell F Graceffa; Shawn P Harriman; Jay F Larrow; Alexander M Long; Matthew W Martin; Michael J Morrison; Vinod F Patel; Philip M Roveto; Ling Wang; Matthew M Weiss; Douglas A Whittington; Yohannes Teffera; Zhiyang Zhao; Anthony J Polverino; Jean-Christophe Harmange
Journal:  J Med Chem       Date:  2008-02-27       Impact factor: 7.446

8.  Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.

Authors:  Jean-Christophe Harmange; Matthew M Weiss; Julie Germain; Anthony J Polverino; George Borg; James Bready; Danlin Chen; Deborah Choquette; Angela Coxon; Tom DeMelfi; Lucian DiPietro; Nicholas Doerr; Juan Estrada; Julie Flynn; Russell F Graceffa; Shawn P Harriman; Stephen Kaufman; Daniel S La; Alexander Long; Matthew W Martin; Sesha Neervannan; Vinod F Patel; Michele Potashman; Kelly Regal; Phillip M Roveto; Michael L Schrag; Charlie Starnes; Andrew Tasker; Yohannes Teffera; Ling Wang; Ryan D White; Douglas A Whittington; Roger Zanon
Journal:  J Med Chem       Date:  2008-03-07       Impact factor: 7.446

Review 9.  Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition.

Authors:  Katherine Holmes; Owain Ll Roberts; Angharad M Thomas; Michael J Cross
Journal:  Cell Signal       Date:  2007-06-12       Impact factor: 4.315

10.  Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.

Authors:  D Strumberg; M E Scheulen; B Schultheis; H Richly; A Frost; M Büchert; O Christensen; M Jeffers; R Heinig; O Boix; K Mross
Journal:  Br J Cancer       Date:  2012-05-08       Impact factor: 7.640

View more
  2 in total

1.  Cytotoxic, Apoptosis-Inducing Activities, and Molecular Docking of a New Sterol from Bamboo Shoot Skin Phyllostachys heterocycla var. pubescens.

Authors:  Reda F A Abdelhameed; Mohamed S Nafie; Ahmed K Ibrahim; Koji Yamada; Maged S Abdel-Kader; Amany K Ibrahim; Safwat A Ahmed; Jihan M Badr; Eman S Habib
Journal:  Molecules       Date:  2020-11-30       Impact factor: 4.411

2.  Design, Synthesis, and In Vitro Evaluation of Benzofuro[3,2-c]Quinoline Derivatives as Potential Antileukemia Agents.

Authors:  Ying Lin; Dong Xing; Wen-Biao Wu; Gao-Ya Xu; Li-Fang Yu; Jie Tang; Yu-Bo Zhou; Jia Li; Fan Yang
Journal:  Molecules       Date:  2020-01-03       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.